Remedium Bio Inc. has entered a multi-target research and development collaboration with Eli Lilly and Company to advance gene therapies for Type 2 diabetes and obesity using its Prometheus™ platform, according to the company. The collaboration brings together Lilly’s metabolic disease expertise and Remedium’s proprietary, subcutaneously administered, dose-adjustable gene delivery system to develop and commercialize one-time treatments designed to provide tunable protein expression with multi-year efficacy, the company said.
Under the agreement, Remedium will receive an upfront payment, equity investment, and potential development and commercialization milestone payments. The company claims it will also be eligible for tiered royalties on global net sales of any resulting products.
Remedium’s Prometheus™ platform enables replacement of a broad range of subcutaneously administered protein treatments with a single injection, adjustable-dose gene therapy at a fraction of current therapeutic costs, the company claims. The therapy is designed for durable, safe, and effective gene delivery with simple post-treatment dose adjustment.
Remedium Bio is based in Lilly Gateway Labs in Boston, part of Lilly’s Catalyze360™ model, which provides early-stage biotech startups with lab space, funding, talent, and development resources.
